Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects - Trial NCT06326723
Access comprehensive clinical trial information for NCT06326723 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. and is currently Completed. The study focuses on Healthy Volunteer. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu Simcere Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Sep 04, 2023
Feb 05, 2024
Primary Outcome
Pharmacokinetic Endpoints1,Pharmacokinetic Endpoints2,Pharmacokinetic Endpoints3,Pharmacokinetic Endpoints4,Pharmacokinetic Endpoints5,Pharmacokinetic Endpoints6,Pharmacokinetic Endpoints7
Summary
This clinical study is a single-center, randomized, double-blind, placebo-controlled Phase 1
 clinical study to assess the PK characteristics and safety and tolerability of single and
 multiple dose daridorexant in 32 healthy adult Chinese subjects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06326723
Non-Device Trial